Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

Trial Profile

Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Pitavastatin (Primary) ; Atorvastatin
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Kowa Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Sep 2009 New trial record.
    • 01 Sep 2009 According to a Kowa Pharmaceutical media release, the company received FDA approval of pitavastatin for the treatment of hypercholesterolemia and combined dyslipidemia in August 2009 and is expected to launch in the US in the first quarter of 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top